Rad51 as a Prognostic Marker in Lung Cancer
Author Information
Author(s): Qiao G-B, Wu Y-L, Yang X-N, Zhong W-Z, Xie D, Guan X-Y, Fischer D, Kolberg H-C, Kruger S, Stuerzbecher H-W
Primary Institution: Lung Cancer Research Institute & Cancer Center, Guangdong Provincial People's Hospital, Guangzhou, P.R. China
Hypothesis
The decreased survival of NSCLC patients with high-level expression of Rad51 is related to an enhanced propensity of tumour cells for survival, antiapoptosis and chemo-/radioresistance.
Conclusion
High-level Rad51 expression in non-small-cell lung cancer patients is associated with poorer survival outcomes.
Supporting Evidence
- High-level Rad51 expression was observed in 29.4% of cases.
- Patients with high-level Rad51 expression had a median survival time of 19 months compared to 68 months for those with low-level expression.
- Rad51 expression was found to be an independent prognostic factor in multivariate analysis.
Takeaway
This study found that patients with high levels of a protein called Rad51 in their lung cancer cells tend to live shorter lives than those with lower levels.
Methodology
The study analyzed Rad51 expression in 383 non-small-cell lung tumors using immunohistochemistry on tissue microarrays.
Limitations
Data on smoking history were missing for the majority of patients.
Participant Demographics
The median age of patients was 59 years, with 71.3% being male.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website